symbol,statement_type,period_end,line_item,value
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Free Cash Flow,2279200000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Repayment Of Debt,-10645100000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Issuance Of Debt,2546300000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Issuance Of Capital Stock,0.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Capital Expenditure,-6643800000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,End Cash Position,1823200000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Other Cash Adjustment Outside Changein Cash,
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Beginning Cash Position,2191900000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Effect Of Exchange Rate Changes,-108800000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Changes In Cash,-259900000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Financing Cash Flow,-4408300000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Net Other Financing Charges,100000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Interest Paid Cff,-4473800000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Cash Dividends Paid,-144700000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Common Stock Dividend Paid,-144700000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Net Preferred Stock Issuance,
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Preferred Stock Issuance,
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Net Common Stock Issuance,0.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Common Stock Issuance,0.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Net Issuance Payments Of Debt,487100000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Net Short Term Debt Issuance,8585900000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Short Term Debt Payments,
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Short Term Debt Issuance,
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Net Long Term Debt Issuance,-8098800000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Long Term Debt Payments,-10645100000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Long Term Debt Issuance,2546300000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Investing Cash Flow,-4774600000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Net Other Investing Changes,163000000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Interest Received Cfi,
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Dividends Received Cfi,463100000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Net Investment Purchase And Sale,1190600000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Sale Of Investment,20040900000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Purchase Of Investment,-18850300000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Net Business Purchase And Sale,
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Purchase Of Business,
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Net PPE Purchase And Sale,-6591300000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Sale Of PPE,52500000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Purchase Of PPE,-6643800000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Operating Cash Flow,8923000000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Taxes Refund Paid,-3343600000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Change In Working Capital,-4877200000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Change In Other Current Liabilities,-127700000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Change In Other Current Assets,-699700000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Change In Payable,182400000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Change In Inventory,-1971200000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Change In Receivables,-2334500000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Other Non Cash Items,3680600000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Stock Based Compensation,480000000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Provisionand Write Offof Assets,87000000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Depreciation And Amortization,8163400000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Depreciation,8163400000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Gain Loss On Investment Securities,-90500000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Net Foreign Currency Exchange Gain Loss,316000000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Gain Loss On Sale Of PPE,-14400000.0
PPLPHARMA.NS,cashflow,2025-03-31 00:00:00,Net Income From Continuing Operations,3417100000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Free Cash Flow,2925000000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Repayment Of Debt,-8613000000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Issuance Of Debt,2401300000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Issuance Of Capital Stock,10500000000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Capital Expenditure,-7120400000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,End Cash Position,2191900000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Other Cash Adjustment Outside Changein Cash,-200000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Beginning Cash Position,532300000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Effect Of Exchange Rate Changes,177900000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Changes In Cash,1481900000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Financing Cash Flow,-4223400000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Net Other Financing Charges,200000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Interest Paid Cff,-4696100000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Cash Dividends Paid,
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Common Stock Dividend Paid,0.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Net Preferred Stock Issuance,
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Preferred Stock Issuance,
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Net Common Stock Issuance,10500000000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Common Stock Issuance,10500000000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Net Issuance Payments Of Debt,-9715300000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Net Short Term Debt Issuance,-3503600000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Short Term Debt Payments,-17709300000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Short Term Debt Issuance,14205700000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Net Long Term Debt Issuance,-6211700000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Long Term Debt Payments,-8613000000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Long Term Debt Issuance,2401300000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Investing Cash Flow,-4340100000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Net Other Investing Changes,-42500000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Interest Received Cfi,
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Dividends Received Cfi,220500000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Net Investment Purchase And Sale,2586300000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Sale Of Investment,19490100000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Purchase Of Investment,-16903800000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Net Business Purchase And Sale,0.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Purchase Of Business,0.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Net PPE Purchase And Sale,-7104400000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Sale Of PPE,16000000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Purchase Of PPE,-7120400000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Operating Cash Flow,10045400000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Taxes Refund Paid,-1568400000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Change In Working Capital,-2343000000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Change In Other Current Liabilities,2306700000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Change In Other Current Assets,427000000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Change In Payable,4043000000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Change In Inventory,-5317500000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Change In Receivables,-3913900000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Other Non Cash Items,4364500000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Stock Based Compensation,274700000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Provisionand Write Offof Assets,-150500000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Depreciation And Amortization,7405600000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Depreciation,7405600000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Gain Loss On Investment Securities,4800000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Net Foreign Currency Exchange Gain Loss,482800000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Gain Loss On Sale Of PPE,4600000.0
PPLPHARMA.NS,cashflow,2024-03-31 00:00:00,Net Income From Continuing Operations,1198000000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Free Cash Flow,-4808600000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Repayment Of Debt,-31862500000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Issuance Of Debt,43846700000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Issuance Of Capital Stock,0.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Capital Expenditure,-9647500000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,End Cash Position,532300000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Other Cash Adjustment Outside Changein Cash,
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Beginning Cash Position,851800000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Effect Of Exchange Rate Changes,51500000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Changes In Cash,-371000000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Financing Cash Flow,8177900000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Net Other Financing Charges,
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Interest Paid Cff,-2781200000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Cash Dividends Paid,-670000000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Common Stock Dividend Paid,-670000000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Net Preferred Stock Issuance,
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Preferred Stock Issuance,
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Net Common Stock Issuance,0.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Common Stock Issuance,0.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Net Issuance Payments Of Debt,11984200000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Net Short Term Debt Issuance,3571400000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Short Term Debt Payments,-14647200000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Short Term Debt Issuance,18218600000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Net Long Term Debt Issuance,8412800000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Long Term Debt Payments,-17215300000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Long Term Debt Issuance,25628100000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Investing Cash Flow,-13387800000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Net Other Investing Changes,-733100000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Interest Received Cfi,0.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Dividends Received Cfi,754100000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Net Investment Purchase And Sale,-3754700000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Sale Of Investment,8479100000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Purchase Of Investment,-12233800000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Net Business Purchase And Sale,-203500000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Purchase Of Business,-203500000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Net PPE Purchase And Sale,-9450600000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Sale Of PPE,196900000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Purchase Of PPE,-9647500000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Operating Cash Flow,4838900000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Taxes Refund Paid,-1890000000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Change In Working Capital,-3020800000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Change In Other Current Liabilities,199700000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Change In Other Current Assets,301400000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Change In Payable,-2716500000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Change In Inventory,-1726400000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Change In Receivables,892600000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Other Non Cash Items,3033400000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Stock Based Compensation,0.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Provisionand Write Offof Assets,-69500000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Depreciation And Amortization,6766900000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Depreciation,6766900000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Gain Loss On Investment Securities,-25600000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Net Foreign Currency Exchange Gain Loss,715600000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Gain Loss On Sale Of PPE,4800000.0
PPLPHARMA.NS,cashflow,2023-03-31 00:00:00,Net Income From Continuing Operations,-1605600000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Free Cash Flow,-1230900000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Repayment Of Debt,-12344200000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Issuance Of Debt,22535500000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Issuance Of Capital Stock,-1000000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Capital Expenditure,-8895100000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,End Cash Position,851800000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Other Cash Adjustment Outside Changein Cash,767400000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Beginning Cash Position,2619700000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Effect Of Exchange Rate Changes,-20400000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Changes In Cash,-2514900000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Financing Cash Flow,7941900000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Net Other Financing Charges,
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Interest Paid Cff,-1445100000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Cash Dividends Paid,-500000000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Common Stock Dividend Paid,-500000000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Net Preferred Stock Issuance,0.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Preferred Stock Issuance,0.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Net Common Stock Issuance,-1000000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Common Stock Issuance,-1000000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Net Issuance Payments Of Debt,10191300000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Net Short Term Debt Issuance,3532500000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Short Term Debt Payments,-9964700000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Short Term Debt Issuance,13497200000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Net Long Term Debt Issuance,6658800000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Long Term Debt Payments,-2379500000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Long Term Debt Issuance,9038300000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Investing Cash Flow,-18121000000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Net Other Investing Changes,-100000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Interest Received Cfi,6800000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Dividends Received Cfi,815900000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Net Investment Purchase And Sale,-1308300000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Sale Of Investment,14030700000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Purchase Of Investment,-15339000000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Net Business Purchase And Sale,-9064500000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Purchase Of Business,-9064500000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Net PPE Purchase And Sale,-8570900000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Sale Of PPE,324200000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Purchase Of PPE,-8895100000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Operating Cash Flow,7664200000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Taxes Refund Paid,-1694200000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Change In Working Capital,-2922900000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Change In Other Current Liabilities,643200000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Change In Other Current Assets,-813900000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Change In Payable,791200000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Change In Inventory,-1756400000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Change In Receivables,-1851700000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Other Non Cash Items,1580400000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Stock Based Compensation,
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Provisionand Write Offof Assets,-526900000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Depreciation And Amortization,5861800000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Depreciation,5861800000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Gain Loss On Investment Securities,-231300000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Net Foreign Currency Exchange Gain Loss,729800000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Gain Loss On Sale Of PPE,5400000.0
PPLPHARMA.NS,cashflow,2022-03-31 00:00:00,Net Income From Continuing Operations,4410300000.0
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Free Cash Flow,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Repayment Of Debt,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Issuance Of Debt,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Issuance Of Capital Stock,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Capital Expenditure,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,End Cash Position,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Other Cash Adjustment Outside Changein Cash,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Beginning Cash Position,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Effect Of Exchange Rate Changes,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Changes In Cash,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Financing Cash Flow,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Net Other Financing Charges,1008500000.0
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Interest Paid Cff,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Cash Dividends Paid,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Common Stock Dividend Paid,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Net Preferred Stock Issuance,750000000.0
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Preferred Stock Issuance,750000000.0
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Net Common Stock Issuance,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Common Stock Issuance,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Net Issuance Payments Of Debt,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Net Short Term Debt Issuance,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Short Term Debt Payments,-3830100000.0
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Short Term Debt Issuance,4733900000.0
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Net Long Term Debt Issuance,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Long Term Debt Payments,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Long Term Debt Issuance,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Investing Cash Flow,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Net Other Investing Changes,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Interest Received Cfi,4900000.0
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Dividends Received Cfi,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Net Investment Purchase And Sale,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Sale Of Investment,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Purchase Of Investment,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Net Business Purchase And Sale,-37751000000.0
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Purchase Of Business,-37751000000.0
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Net PPE Purchase And Sale,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Sale Of PPE,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Purchase Of PPE,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Operating Cash Flow,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Taxes Refund Paid,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Change In Working Capital,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Change In Other Current Liabilities,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Change In Other Current Assets,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Change In Payable,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Change In Inventory,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Change In Receivables,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Other Non Cash Items,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Stock Based Compensation,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Provisionand Write Offof Assets,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Depreciation And Amortization,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Depreciation,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Gain Loss On Investment Securities,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Net Foreign Currency Exchange Gain Loss,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Gain Loss On Sale Of PPE,
PPLPHARMA.NS,cashflow,2021-03-31 00:00:00,Net Income From Continuing Operations,
